logo

Avrobio, Inc. (AVRO)



Trade AVRO now with
  Date
  Headline
1/7/2019 7:07:22 AM AVROBIO Appoints Philip Vickers To Its Board
12/19/2018 7:13:01 AM AVROBIO Gets Orphan-Drug Designation From US FDA For AVR RD 01 For Treatment Of Fabry Disease
12/18/2018 7:08:06 AM AVROBIO Announces Grant Of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11/15/2018 6:30:18 AM Wedbush Is Lowering AVROBIO, INC. (AVRO) FY19 Estimate To -2.54 From -2.37
11/15/2018 6:30:04 AM Wedbush Is Lowering AVROBIO, INC. (AVRO) Q4 19 Estimate To -0.62 From -0.58
11/15/2018 6:29:50 AM Wedbush Is Cutting AVROBIO, INC. (AVRO) Q3 19 Estimate To -0.61 From -0.55
11/15/2018 6:29:38 AM Wedbush Is Lowering AVROBIO, INC. (AVRO) Q2 19 Estimate To -0.68 From -0.64
11/15/2018 6:29:25 AM Wedbush Is Cutting AVROBIO, INC. (AVRO) Q1 19 Estimate To -0.63 From -0.60
11/15/2018 6:29:11 AM Wedbush Is Raising AVROBIO, INC. (AVRO) FY18 Estimate To -4.57 From -4.70
11/15/2018 6:28:54 AM Wedbush Is Increasing AVROBIO, INC. (AVRO) Q4 18 Estimate To -0.60 From -0.64
11/15/2018 6:28:29 AM Wedbush Reiterates AVROBIO, INC. (AVRO) At Outperform With $43 Price Target
11/13/2018 8:30:40 AM AVROBIO Q3 Net Loss $11.6 Mln
10/1/2018 7:12:36 AM AVROBIO Reports Updated Clinical Data For AVR-RD-01 Gene Therapy In Fabry Disease
10/1/2018 7:03:25 AM AVROBIO Getss No Objection To CTA From Health Canada For AVR-RD-02 Gene Therapy For Gaucher Disease
8/9/2018 8:19:33 AM AVROBIO Q2 Loss Per Share $2.98 Vs Loss $1.15 Prior Year
7/16/2018 6:14:23 AM Wedbush Initiates AVROBIO, INC. (AVRO) At Outperform With $38 Price Target